HighPassBio is focused on developing innovative therapies for hematological malignancies, particularly through the use of T cell receptor (TCR)-engineered T cells, also known as TCR T cells. Their lead program aims to treat or prevent the relapse of leukemia in patients who have undergone hematopoietic stem cell transplantation (HSCT). This approach utilizes TCRs to target HA-1 expressing tumors, which are specific to the patient's leukemic cells, thereby enhancing the immune response against the cancer. The technology was developed at the Fred Hutchinson Cancer Research Center under the guidance of Dr. Marie Bleakley, a recognized expert in the field.

The TCR-engineered T cell therapy represents a significant advancement in adoptive T cell therapy, as it allows for the recognition of a broader range of tumor antigens compared to traditional CAR T cell therapies. By identifying and engineering TCRs that can specifically target minor histocompatibility antigens like HA-1, HighPassBio aims to provide a potent and selective treatment option for patients at high risk of relapse post-HSCT. The company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this novel immunotherapy in both adult and pediatric patients who have experienced leukemia relapse following blood and marrow transplantation.

United States

HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The company’s lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.

HighPassBio

Company Details